FT-104 explained

FT-104 (also known as RE-104 and 4-glutaryloxy-N,N-diisopropyltryptamine) is a psychedelic tryptamine derivative which is a prodrug ester of the well known designer drug 4-HO-DiPT.^[1] It is one of a number of related derivatives developed for potential medical applications, and is in human clinical trials as a possible treatment for postpartum depression and treatment-resistant depression.^{[2] [3] [4] [5]}

It is being developed by the pharmaceutical company Reunion Neuroscience.^[6]  As of 2024, FT-104 is entering Phase II clinical trials for post-partum depression.^[7]

Pharmacology

FT-104 is a prodrug that is converted into the psychedelic tryptamine 4-HO-DiPT upon administration.^{[1] [8]}  4-OH-DiPT then acts as an agonist on the serotonin 2A receptor which leads to an antidepressant effect.^[6]

See also

• Indopan, an antidepressant developed by the Upjohn pharmaceutical company in the 1960s.
• Monase, an antidepressant developed by the Upjohn pharmaceutical company in the 1960s.
• 4-AcO-DiPT
• 4-PrO-DMT
• THC hemisuccinate

Notes and References

1. Bryson N, Alexander R, Asnis-Alibozek A, Ehlers MD . RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine . ACS Chemical Neuroscience . 15 . 12 . 2386–2395 . June 2024 . 38758589 . 11191588 . 10.1021/acschemneuro.4c00058 .
2. Web site: Hallifax J . An Inside Look into Field Trip's Next-Generation Psychedelic, FT-104 . 11 August 2022 .
3. Tryptamine prodrugs . WO . 2022/000091 . Bryson N . Field Trip Psychedelics Inc. . 6 January 2022 .
4. Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders. . Slassi A, Araujo J . US . 2022/0024956 . Mindset Pharma Inc. . 27 January 2022 .
5. Hallucinogen-Fatty Acid Combination . Slassi A, Araujo J, Higgin GH, Gabriele J. WO . 2022/246572 . 1 December 2022 . Mindset Pharma Inc. .
6. News: Braner S . Reunion Neuroscience raises $103 million for a psychedelic to treat depression . . May 8, 2024 .
7. News: Alexander R, Hocevar-Trnka J . RE104: A Novel, Fast-Acting Psychedelic for Postpartum Depression . June 26, 2024 . psychiatrictimes.com .
8. News: Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders . May 20, 2024 . Yahoo!Finance . GlobalNewswire .